{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T09:34:48Z","timestamp":1720517688964},"reference-count":23,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1016\/j.transproceed.2009.06.097","type":"journal-article","created":{"date-parts":[[2009,7,11]],"date-time":"2009-07-11T08:23:45Z","timestamp":1247300625000},"page":"S18-S20","source":"Crossref","is-referenced-by-count":3,"special_numbering":"S","title":["Mammalian Target of Rapamycin and Autosomal Dominant Polycystic Kidney Disease"],"prefix":"10.1016","volume":"41","author":[{"given":"R.P.","family":"W\u00fcthrich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.L.","family":"Serra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2009.06.097_bib1","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMcp0804458","article-title":"Clinical practice","volume":"359","author":"Grantham","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transproceed.2009.06.097_bib2","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1146\/annurev.med.60.101707.125712","article-title":"Polycystic kidney disease","volume":"60","author":"Harris","year":"2009","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.transproceed.2009.06.097_bib3","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1093\/ndt\/gfm426","article-title":"Molecular pathogenesis of ADPKD and development of targeted therapeutic options","volume":"22","author":"Ibraghimov-Beskrovnaya","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.transproceed.2009.06.097_bib4","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","article-title":"Autosomal dominant polycystic kidney disease","volume":"369","author":"Torres","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.transproceed.2009.06.097_bib5","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.semnephrol.2008.03.003","article-title":"Vasopressin antagonists in polycystic kidney disease","volume":"28","author":"Torres","year":"2008","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.transproceed.2009.06.097_bib6","doi-asserted-by":"crossref","first-page":"5247","DOI":"10.1073\/pnas.0601352103","article-title":"mTOR is out of control in polycystic kidney disease","volume":"103","author":"Mostov","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.transproceed.2009.06.097_bib7","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1073\/pnas.0509694103","article-title":"The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease","volume":"103","author":"Shillingford","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.transproceed.2009.06.097_bib8","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1681\/ASN.2004080660","article-title":"Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease","volume":"16","author":"Tao","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.transproceed.2009.06.097_bib9","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1093\/ndt\/gfi181","article-title":"Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD)","volume":"2","author":"Wahl","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.transproceed.2009.06.097_bib10","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1159\/000104818","article-title":"Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease","volume":"30","author":"Wu","year":"2007","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.transproceed.2009.06.097_bib11","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1093\/ndt\/gfl246","article-title":"Therapeutic approaches in autosomal dominant polycystic kidney disease (ADPKD): is there light at the end of the tunnel?","volume":"21","author":"Walz","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.transproceed.2009.06.097_bib12","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1046\/j.1523-1755.2001.00768.x","article-title":"Angiogenesis in autosomal-dominant polycystic kidney disease","volume":"60","author":"Bello-Reuss","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.transproceed.2009.06.097_bib13","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/sj.ki.5001725","article-title":"Evidence of angiogenesis and microvascular regression in autosomal-dominant polycystic kidney disease kidneys: a corrosion cast study","volume":"70","author":"Wei","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.transproceed.2009.06.097_bib14","doi-asserted-by":"crossref","first-page":"830","DOI":"10.2353\/ajpath.2007.060455","article-title":"Involvement of hypoxia-inducible transcription factors in polycystic kidney disease","volume":"170","author":"Bernhardt","year":"2007","journal-title":"Am J Pathol"},{"key":"10.1016\/j.transproceed.2009.06.097_bib15","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1093\/ndt\/gfm697","article-title":"Sirolimus ameliorates the enhanced expression of metalloproteinases in a rat model of autosomal dominant polycystic kidney disease","volume":"23","author":"Berthier","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.transproceed.2009.06.097_bib16","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm0202-128","article-title":"Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor","volume":"8","author":"Guba","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.transproceed.2009.06.097_bib17","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2369-8-13","article-title":"Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study","volume":"8","author":"Serra","year":"2007","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.transproceed.2009.06.097_bib18","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/ki.1983.51","article-title":"Rate of functional deterioration in polycystic kidney disease","volume":"23","author":"Franz","year":"1983","journal-title":"Kidney Int"},{"key":"10.1016\/j.transproceed.2009.06.097_bib19","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1056\/NEJMoa054341","article-title":"Volume progression in polycystic kidney disease","volume":"354","author":"Grantham","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transproceed.2009.06.097_bib20","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/ki.2008.558","article-title":"Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months","volume":"75","author":"Kistler","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.transproceed.2009.06.097_bib21","doi-asserted-by":"crossref","first-page":"148","DOI":"10.2215\/CJN.00330705","article-title":"Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes","volume":"1","author":"Grantham","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.transproceed.2009.06.097_bib22","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1681\/ASN.2007050626","article-title":"Sirolimus reduces polycystic liver volume in ADPKD patients","volume":"19","author":"Qian","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.transproceed.2009.06.097_bib23","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/01.TP.0000184006.43152.8D","article-title":"Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies","volume":"80","author":"Kauffman","year":"2005","journal-title":"Transplantation"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004113450900829X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004113450900829X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T12:53:01Z","timestamp":1545137581000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004113450900829X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["S004113450900829X"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2009.06.097","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2009,7]]}}}